NEW YORK (GenomeWeb News) – Illumina said in a regulatory filing after the close of the market on Thursday that it has received a second request from the US Federal Trade Commission for additional information related to the company’s effort to acquire Complete Genomics.

Separately, BGI-Shenzhen said also on Thursday that it has extended its cash tender offer for Complete Genomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.